NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,384−0.08%BTC$76,220+0.09%VIX15.44−12.82%live tape · as of 23:00 UTC · 17 Sep
The Screen · Healthcare · Medical Care Facilities
Tenet Healthcare Corp
THC · the NYSE · USD · Market cap $21.2B · 77,000 employees
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States.
FAIL · Does not pass the screen
263.49 USD
At the last full screen 2026-09-03
Screened 2026-09-03 · the tape above runs as of 23:00 UTC · 17 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Tenet Healthcare Corp holds its Markdown at $263.49. The statistical read favours the sellers, held for 58 days.
As held on the ledger · 2026-09-03
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 58 days
Price at the screen
$263.49
Valuation
10.18 trailing · 12.50 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.23
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
44.38%
Below 33%
Interest-bearing debt is 44.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
18.36%
Below 49%
Money owed to the company is 18.4% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-03 screen. The gold marker is the market price at the same screen. A 5.1% margin of safety to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +8% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-03 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
US Hospitals Run Well Yet Offer No Edge
Think of a regional hospital network where patients keep arriving and bills get paid, yet every new clinic or rival network chips away at the same pool of revenue. Tenet shows an 8 percent profit margin, 3 percent revenue growth and a narrow moat that leaves it exposed to reimbursement changes and local competition. With only an 8 percent margin of safety at the current price and no clear opportunity, the solid 30 percent ROE and ethical pass are not enough to move us.
Forward earnings sit at 11 times, which looks reasonable until you weigh the limited growth runway and the fact that analysts already price in better days with a median target well above fair value.
The main risk lies in healthcare policy shifts that can squeeze volumes or rates without warning, turning a steady operation into a thinner one quickly. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
THC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-14Markdown · changed$263.49+0.3%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it strong buy, with a mean price target of $244.
2026-08-14Markup · changed$262.63+62.1%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 62.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it strong buy, with a mean price target of $244.
2026-07-18Distribution$162.06+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (21 analysts) rates it strong buy, with a mean price target of $244.
2026-07-03Distribution$162.06+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$162.06Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
